Project Grant R00HL166773
Award Date 6/1/26
Completion Date 4/30/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- Federal Grant Award Summary Mayo Clinic received a $1,340,300 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period August 1, 2025, through May 31, 2029. The project, titled "Discovering Aging-Associated Genetic Modifiers and Therapies for Anthracycline-Induced Cardiotoxicity," aims to identify genetic factors that modify susceptibility to anthracycline-induced cardiotoxicity...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a Project Grant valued at $715,378 on August 18, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The grant funds research to elucidate the molecular mechanisms by which cardiac myosin and cardiac myosin-binding protein-C (cMyBP-C) regulate force generation in cardiac muscle contraction. The research will be conducted through a multidisciplinary approach...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Regents of the University of Michigan a Project Grant totaling $444,775 (Award Date: June 1, 2026; Completion Date: April 30, 2031) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardiotoxicity mechanisms of osimertinib and develop therapeutic interventions. The project will deliver research findings on how this kinase inhibitor—the sole approved therapy...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $706,519 Project Grant to the University of Pittsburgh under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2025, with completion expected by June 30, 2030. This award funds research investigating the non-canonical roles of NIPBL (Nipped-B-Like protein) in cardiomyocytes to address a critical knowledge gap in Cornelia de Lange Syndrome (CDLS) cardiac disease mechanisms. The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a Project Grant totaling $694,466 under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanistic role of mitochondrial BK (mitoBK) channels in cardiac physiology and protection against pathological cardiac hypertrophy. The award, obligated on September 5, 2025, with completion targeted for June 30, 2029, funds research aimed at establishing the...
- Federal Grant Award Summary Mayo Clinic Arizona, through funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is conducting a four-year research project investigating the role of Programmed Cell Death 4 (PDCD4) in doxorubicin-induced cardiotoxicity. The $695,997 project grant, awarded August 18, 2025, and extending through May 31, 2029, focuses on understanding how PDCD4 functions as a cardioprotective molecule...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $773,479 Project Grant to Harvard College's Office for Sponsored Programs on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into mitochondrial gene editing in human cardiomyocytes, with completion anticipated by May 31, 2029. The project delivers a novel Cas9-based mitochondrial gene editor system (MEDITORS) designed to introduce, regulate, and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $811,885 to the J. David Gladstone Institutes under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025. The award funds research to elucidate epigenomic mechanisms of cardiac fibrosis and heart failure pathogenesis, with a completion date of May 31, 2029. The research leverages novel genetic mouse models, advanced transcriptional and epigenomic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University a Project Grant totaling $768,567 (awarded September 15, 2025; completion date August 31, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate positron emission tomography (PET) imaging technology for early detection of chemotherapy-induced cardiotoxicity. The primary deliverable is the advancement of 68GA-GALMYDAR, a novel PET tracer...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Maryland, Baltimore a $777,016 Project Grant on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research through May 31, 2029. This project aims to deliver functional characterization and validation of genetic variants associated with hypoplastic heart syndrome (HHS), a severe congenital heart disease affecting approximately 1 in 5,000...